摘要
The aim of this study was to summarize the efficacy and tolerability of rotigotine in the treatment of primary restless legs syndrome（RLS）. Pub Med, EMBASE, and Cochrane Central Register of Controlled Trials（CENTRAL） were searched for English-language randomized controlled trials（RCTs） that assessed the effectiveness of rotigotine for RLS. The pooled mean change from baseline in International RLS（IRLS） Study Group Rating Scalescore and relative risk（RR） of response based on the Clinical Global Impression-Improvement（CGI-I） scale score were applied to evaluate the outcomes. The pooled proportions of adverse events（AEs） were also estimated. Six RCTs were included. The meta-analysis showed a favorable effectiveness of rotigotine versus placebo on RLS [mean change on IRLS score： mean difference（MD）=–4.80; 95% confidence interval（CI）： –5.90 to –3.70; P〈0.00001 and RR of response on CGI-I was 2.19; 95% CI： 1.86 to 2.58, P〈0.00001]. The most common AEs were application site reactions, nausea, headache and fatigue. In general, rotigotine was well-tolerated in patients with primary RLS. Based on the findings from the meta-analysis, rotigotine was more significantly efficacious in the treatment of RLS than placebo. Nevertheless, long-term studies and more evidence of comparisons of rotigotine with other dopamine agonists are needed.
The aim of this study was to summarize the efficacy and tolerability of rotigotine in the treatment of primary restless legs syndrome（RLS）. Pub Med, EMBASE, and Cochrane Central Register of Controlled Trials（CENTRAL） were searched for English-language randomized controlled trials（RCTs） that assessed the effectiveness of rotigotine for RLS. The pooled mean change from baseline in International RLS（IRLS） Study Group Rating Scalescore and relative risk（RR） of response based on the Clinical Global Impression-Improvement（CGI-I） scale score were applied to evaluate the outcomes. The pooled proportions of adverse events（AEs） were also estimated. Six RCTs were included. The meta-analysis showed a favorable effectiveness of rotigotine versus placebo on RLS [mean change on IRLS score： mean difference（MD）=–4.80; 95% confidence interval（CI）： –5.90 to –3.70; P〈0.00001 and RR of response on CGI-I was 2.19; 95% CI： 1.86 to 2.58, P〈0.00001]. The most common AEs were application site reactions, nausea, headache and fatigue. In general, rotigotine was well-tolerated in patients with primary RLS. Based on the findings from the meta-analysis, rotigotine was more significantly efficacious in the treatment of RLS than placebo. Nevertheless, long-term studies and more evidence of comparisons of rotigotine with other dopamine agonists are needed.
